Search

Your search keyword '"Afzali, Anita"' showing total 7 results
Start Over Author "Afzali, Anita" Publication Type Magazines
7 results on '"Afzali, Anita"'

1. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Author

Danese, Silvio, Panaccione, Remo, Feagan, Brian G, Afzali, Anita, Rubin, David T, Sands, Bruce E, Reinisch, Walter, Panés, Julián, Sahoo, Aparna, Terry, Natalie A, Chan, Daphne, Han, Chenglong, Frustaci, Mary Ellen, Yang, Zijiang, Sandborn, William J, Hisamatsu, Tadakazu, Andrews, Jane M, D'Haens, Geert R, Oliinyk, Oleksandr, Bilianskyi, Leonid, Gniady-Jastrzebska, Jadwiga, Petryka, Robert, Arlukowicz, Tomasz, Gietka, Piotr, Zmudzinski, Marcin, Mumtaz, Syed, Wolf, Douglas, Wojcik, Katarzyna, Duvall, George, Augustyn, Monika, Filip, Rafal, Tarabar, Dino, Tkachev, Alexander, Seidler, Ursula, Zittan, Eran, Pokrotnieks, Juris, Shchukina, Oksana, Machavariani, Andro, Loy, Laura, Abu-farsakh, Niazy, Marina, Pesegova, Sreckovic, Slobodan, Laclav, Martin, Wei, Shu-Chen, Suiter, Daniel, Borsuk, Aleksey, Hebuterne, Xavier, Buning, Carsten, Lahat-Zok, Adi, Danilkiewicz, Wit, Frysna, Bernadetta, Jovicic, Ivana, Datsenko, Olena, Guram, Maninder, Jain, Animesh, Rashid, Zahid, Heeren, Sonja, Shulga, Natallia, Timkin, Ivan, Gornjakovic, Srdjan, Lukas, Milan, Altwegg, Romain, Desjeux, Ariadne, Reimund, Jean-Marie, Giorgadze, Manana, Jochum, Christoph, Ito, Hiroaki, Nakai, Katsuhiko, Takagi, Tomohisa, Zaha, Osamu, Choi, Changhwan, Kim, Taeoh, Lee, Jonghun, Stundiene, Ieva, Hilmi, Ida Normiha, Hj Md Said, Rosaida, Leszczyszyn, Jaroslaw, Abdulganieva, Diana, Fominykh, Yulia, Maksyashina, Svetlana, Balaz, Jozef, Van Domselaar, Manuel, Kav, Taylan, Dennis, Patrick, Henry, Patricia, Holmes, Robert, Johnson, Christopher, McBride, Matthew, Sarles, Harry, Moore, Gregory, Yakubtsevich, Ruslan, Muls, Vinciane, Trbojevic, Stevan, Afif, Waqqas, Bernstein, Charles, Klarin, Ivo, Serclova, Zuzana, Volfova, Miroslava, Desreumaux, Pierre, Gilletta de Saint Joseph, Cyrielle, Roblin, Xavier, Vuitton, Lucine, Chelidze, Kakhaber, Kuehbacher, Tanja, Koutroubakis, Ioannis, Cicala, Michele, Fries, Walter, Gasbarrini, Antonio, Aoyama, Nobuo, Hayashi, Yoshito, Hirai, Fumihito, Horiki, Norkiyuki, Hoshi, Namiko, Inaba, Tomoki, Hiroyasu, Ishida, Maemoto, Atsuo, Matsumoto, Takayuki, Matsushima, Kayoko, Motoya, Satoshi, Taruishi, Masaki, Rashid, Mohammed, Chun, Jaeyoung, Kim, Young-Ho, Park, Dong Il, Sharara, Ala, Jonaitis, Laimas, Deriban, Gjorgi, Brooker, James, Gawdis-Wojnarska, Beata, Wozniak-Stolarska, Barbara, Andreev, Pavel, Simanenkov, Vladimir, Trofimov, Vasiliy, Jovanovic, Igor, Zdravkovic, Natasa, Aldeguer i Mante, Xavier, Hernandez Ramirez, Vicent, Akpinar, Hale, Celebi, Gurkan, Hamzaoglu, Hulya, Fernandez, Juan, Kamath, Jayaprakash, Palekar, Nicole, Pruthi, Jatinder S., Rausher, David, and Ritter, Timothy

Abstract

Many patients with moderately to severely active Crohn's disease do not respond to available therapies or lose response over time. The GALAXI-1 study previously found that three intravenous guselkumab dosages showed superior clinical and endoscopic outcomes over placebo at week 12 in patients with moderately to severely active Crohn's disease. We report the safety and efficacy of subcutaneous guselkumab maintenance regimens to week 48 in the GALAXI-1 study.

Published
2024
Full Text
View/download PDF

3. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Author

Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Allez, Matthieu, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob, Behrend, Clint, Bezemer, Geert, Bonnaud, Guillaume, Brankovic, Marija, Byung, Ik Jang, Calvet Calvo, Xavier, Chachu, Karen, Chebli, Julio Maria Fonseca, Cheon, Jae Hee, Cichoz-Lach, Halina, Clark, Larry, Cummings, Fraser, Dalal, Kunal, Danese, Silvio, De Boer, Nanne, De Lourdes Ferrari, Maria, Désilets, Etienne, Dugalic, Predrag, Duvall, George, Fedorishina, Olga, Filip, Rafal, Flores, Cristina, Fogel, Ronald, Fon, James, Frankel, Michael, Friedenberg, Keith, Fries, Walter, Galina, Vassileva, Gietka, Piotr, Goel, Rishi, Hasselblatt, Peter, Herfarth, Hans, Herszényi, László, Hindryckx, Pieter, Hoentjen, Frank, Horjus Talabur Horje, Carmen, Iduru, Satish, Irving, Peter, Isfort, Robert, Jairath, Vipul, Jones, Michael, Kalimullina, Dilara, Katz, Jeffry, Kaur, Manreet, Khurana, Sunil K, Kim, Joo Sung, Kim, Youngho, Kleczkowski, Dariusz, Knezevic, Slavko, Knoll, Aaron, Korman, Louis Y, Kotzev, Iskren, Kulyapin, Andrey, Lee, Kang Moon, Leemreis, Desiree, Leszczyszyn, Jaroslaw, Limdi, Jimmy, Lissauer, Jack, Loftus, Edward, Malecka-Panas, Ewa, Marshall, John, Mihály, Emese, Milan, Lukas, Monteleone, Giovanni, Nagorni, Aleksandar, Owczarek, Danuta, Palekar, Nichole, Panaccione, Remo, Park, Young Soo, Park, Sang Hyoung, Parra, Rogério, Patai, Árpád, Patel, Kamal, Patel, Bhaktasharan, Pershko, Anatoly, Petrova, Elina, Pineton de Chambrun, Guillaume, Randall, Charles, Riestra Menendez, Sabino, Ritter, Timothy, Rivero, Montserrat, Roblin, Xavier, Rocca, Rodolfo, Romatowski, Jacek, Rydzewska, Grazyna, Saibeni, Simone, Salzberg, Bruce, Sarles, Harry, Saunders, John, Savarino, Edoardo Vincenzo, Serclova, Zuzana, Shchukina, Oksana, Siegel, Jonathan, Soofi, Najm, Sparrow, Miles, Stokesberry, David, Suiter, Daniel, Svorcan, Petar, Tkachev, Alexander, Tsonev, Nikolay, Tünde, Kristóf, Ulbrych, Jan, Vanasek, Tomas, Varga, Márta, Vermeire, Severine, Vicente Lidon, Raquel, Weiss, Michael L, Wesley, Emma, Winstead, Nathaniel, Wojcik, Katarzyna, Wypych, Joanna, Zaltman, Cyrla, and Zdena, Zadorova

Abstract

Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.

Published
2022
Full Text
View/download PDF

4. Predicting Suboptimal Transitions in Adolescents With Inflammatory Bowel Disease

Author

Pearlstein, Haley, Bricker, Josh, Michel, Hilary K., Afzali, Anita, Donegan, Amy M., Maltz, Ross M., Boyle, Brendan M., and Dotson, Jennifer L.

Abstract

Adolescents and young adults (AYAs) are at risk for disease exacerbations and increased health care utilization around the time of transition to adult care. Our aim was to identify risk factors predictive of a suboptimal transition for AYA with inflammatory bowel disease. We performed a retrospective chart review of patients with pediatric inflammatory bowel disease transferred to adult care from our institution in 2016 and 2017, recording demographic, psychosocial, and disease-specific data. Post-transfer data were obtained via the health care information exchange from the adult provider within our electronic medical record. We defined suboptimal transition as either a return to pediatric care or requiring care escalation within 1 year of transfer. Out of 104 subjects 37 (36%) were found to have had a suboptimal transition. Our models suggest that a suboptimal transition is associated with several risk factors including any mental health diagnosis (odds ratio [OR] = 4.15; 95% confidence interval [95% CI]: 1.18–14.59), history of medication nonadherence (OR = 5.15 [95% CI: 1.52–17.42]), public insurance (OR = 6.60 [95% CI: 1.25–34.96]), higher Physician Global Assessment score at time of transition (OR = 6.64 [95% CI: 1.60–27.58], and short Pediatric Crohn Disease Activity Index scores (OR = 1.17 [95% CI: 1.03–1.33]). Higher hemoglobin levels at transition were protective (OR = 0.69 [95% CI: 0.48–0.98]). Age at time of transition, disease duration, and medication type at transition were not found to be associated with transition outcomes. AYA with public insurance, a mental health history, medication nonadherence, and evidence of active disease may be at greater risk for suboptimal and poor health outcomes at transition.

Published
2021
Full Text
View/download PDF

5. Women’s Health and Ulcerative Colitis

Author

Clark-Snustad, Kindra, Butnariu, Madalina, and Afzali, Anita

Abstract

Although ulcerative colitis affects males and females at similar rates, certain sex-specific differences influence the disease-related risks and experiences of females with ulcerative colitis. This article reviews topics that affect females with ulcerative colitis, including the impact of disease on the menstrual cycle, fertility, child bearing, sexual health, and recommendations for health care maintenance.

Published
2020
Full Text
View/download PDF

7. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting

Author

Afzali, Anita, Ogden, Kristine, Friedman, Michael L., Chao, Jingdong, and Wang, Anthony

Abstract

AbstractAims:Inflammatory bowel disease (IBD) (e.g. ulcerative colitis [UC] and Crohn’s disease [CD]) severely impacts patient quality-of-life. Moderate-to-severe disease is often treated with biologics requiring infusion therapy, adding incremental costs beyond drug costs. This study evaluates US hospital-based infusion services costs for treatment of UC or CD patients receiving infliximab or vedolizumab therapy.Materials and methods:A model was developed, estimating annual costs of providing monitored infusions using an activity-based costing framework approach. Multiple sources (published literature, treatment product inserts) informed base-case model input estimates.Results:The total modeled per patient infusion therapy costs in Year 1 with infliximab and vedolizumab was $38,782 and $41,320, respectively, and Year 2+, $49,897 and $36,197, respectively. Drug acquisition cost was the largest total costs driver (90–93%), followed by costs associated with hospital-based infusion provision: labor (53–56%, non-drug costs), allocated overhead (23%, non-drug costs), non-labor (23%, non-drug costs), and laboratory (7–10%, non-drug costs).Limitations:Limitations included reliance on published estimates, base-case cost estimates infusion drug, and supplies, not accounting for volume pricing, assumption of a small hospital infusion center, and that, given the model adopts the hospital perspective, costs to the patient were not included in infusion administration cost base-case estimates.Conclusions:This model is an early step towards a framework to fully analyze infusion therapies’ associated costs. Given the lack of published data, it would be beneficial for hospital administrators to assess total costs and trade-offs with alternative means of providing biologic therapies. This analysis highlights the value to hospital administrators of assessing cost associated with infusion patient mix to make more informed resource allocation decisions. As the landscape for reimbursement changes, tools for evaluating the costs of infusion therapy may help hospital administrators make informed choices and weigh trade-offs associated with providing infusion services for IBD patients.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results